Decaris Martin L, Emson Claire L, Li Kelvin, Gatmaitan Michelle, Luo Flora, Cattin Jerome, Nakamura Corelle, Holmes William E, Angel Thomas E, Peters Marion G, Turner Scott M, Hellerstein Marc K
Department of Fibrosis, KineMed Inc., Emeryville, California, United States of America.
Department of Medicine, Division of Gastroenterology, University of California San Francisco, San Francisco, California, United States of America.
PLoS One. 2015 Apr 24;10(4):e0123311. doi: 10.1371/journal.pone.0123311. eCollection 2015.
Accumulation and degradation of scar tissue in fibrotic liver disease occur slowly, typically over many years. Direct measurement of fibrogenesis, the rate of scar tissue deposition, may provide valuable therapeutic and prognostic information. We describe here results from a pilot study utilizing in vivo metabolic labeling to measure the turnover rate of hepatic collagen and collagen-associated proteins in plasma for the first time in human subjects. Eight subjects with chronic liver disease were labeled with daily oral doses of 2H2O for up to 8 weeks prior to diagnostic liver biopsy and plasma collection. Tandem mass spectrometry was used to measure the abundance and fractional synthesis rate (FSR) of proteins in liver and blood. Relative protein abundance and FSR data in liver revealed marked differences among subjects. FSRs of hepatic type I and III collagen ranged from 0.2-0.6% per day (half-lives of 4 months to a year) and correlated significantly with worsening histologic fibrosis. Analysis of plasma protein turnover revealed two collagen-associated proteins, lumican and transforming growth factor beta-induced-protein (TGFBI), exhibiting FSRs that correlated significantly with FSRs of hepatic collagen. In summary, this is the first direct measurement of liver collagen turnover in vivo in humans and suggests a high rate of collagen remodeling in advanced fibrosis. In addition, the FSRs of collagen-associated proteins in plasma are measurable and may provide a novel strategy for monitoring hepatic fibrogenesis rates.
纤维化肝病中瘢痕组织的积累和降解过程缓慢,通常需要数年时间。直接测量纤维生成,即瘢痕组织沉积的速率,可能会提供有价值的治疗和预后信息。我们在此描述一项初步研究的结果,该研究首次在人类受试者中利用体内代谢标记来测量肝脏胶原蛋白和血浆中胶原蛋白相关蛋白的周转率。八名慢性肝病患者在进行诊断性肝活检和采集血浆之前,连续8周每日口服2H2O进行标记。采用串联质谱法测量肝脏和血液中蛋白质的丰度和分数合成率(FSR)。肝脏中的相对蛋白质丰度和FSR数据显示,受试者之间存在显著差异。肝脏I型和III型胶原蛋白的FSR范围为每天0.2 - 0.6%(半衰期为4个月至1年),并且与组织学纤维化的恶化显著相关。血浆蛋白周转率分析显示,两种胶原蛋白相关蛋白,即核心蛋白聚糖和转化生长因子β诱导蛋白(TGFBI),其FSR与肝脏胶原蛋白的FSR显著相关。总之,这是首次在人体内直接测量肝脏胶原蛋白的周转率,表明晚期纤维化中胶原蛋白重塑率很高。此外,血浆中胶原蛋白相关蛋白的FSR是可测量的,可能为监测肝脏纤维生成速率提供一种新策略。